UCI Anti-Cancer Challenge Research Projects

First and foremost, thank you so much for your past support of the UCI Anti-Cancer Challenge. You have made a huge impact which will lead to better treatments and cures for cancers. Please consider making a donation to help us achieve our 2021 goal of raising $200,000 to fund four cancer research projects. While there wasn’t an in-person walk in 2021, we invite you to join the Millers, Benjamins, Wagners and Goons in-person for at the reception at UCI’s Chao Family Comprehensive Cancer Center research lab in Irvine. 

Tuesday, October 5, 2021: 5 p.m. - 7 p.m. 

UC Irvine Sprague Hall: 839 Medical Sciences Court, Irvine, CA 92697-4047

Hear from the cancer researchers you’ve supported through the Anti-Cancer Challenge 

Tour the cancer research labs

Enjoy drinks, hors d'oeuvres and good company

To RSVP CLICK HERE

Please know that YOU have propelled research forward. 

To date, the Anti-Cancer Challenge has funded more than $2.2 million in research grant awards advancing more than five dozen promising cancer pilot studies and early-phase clinical trials. These investigations produce knowledge and insights into cancer research that not only impact the community, but also patients seen at the Chao Family Comprehensive Cancer Center. Awards have resulted in the following:

• Extramural funding totaling $21.9 million was awarded to UCI researchers for grants that stemmed from their Anti-Cancer Challenge pilot projects.
• Six clinical trials began accruing patients. These trials addressed opportunities to improve cancer treatment related to the brain, mouth, blood, colon and gastrointestinal tract.
• Five studies addressed specific community needs. These ranged from evaluating social media as a means to increase preventive cancer screenings among Vietnamese families in Orange County and interventions to reduce adverse outcomes in young adult Hispanic men with testicular cancer.
• Two Irvine-based start-up companies began operations to pursue concepts from funded projects. GLYTR Therapeutics is developing a novel immunotherapy platform technology that targets diverse cancer types, ranging from breast cancer to leukemia. Siege Pharmaceuticals is exploring new cancer drugs based on a naturally occurring molecule that starves cancer cells to death.

With much appreciation, 

Shawn Miller, Ronit Benjamin, Steve Wagner and Lisa Goon

Please contact anti-cancerchallenge@uci.edu with any questions.